Proxi Biotech ApS
CVR 39859211 · Private limited company (ApS) · Active · Low risk
Proxi Biotech ApS is a Private limited company (ApS), founded on , based in København V. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.0% over the next 12 months, which is 0.7 times the average for Danish companies. 8 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -1.7m and a net result of DKK -1.7m. CEO: Aria Aminzadeh.
Bankruptcy risk for Proxi Biotech ApS
0.7 × the average (1.41%) · higher risk than 72% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 39859211
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (8 years)
- Address
- c/o René Jørgensen, Skjalm Hvides Gade 12, 3. th
1728 København V - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 40k
- Auditor
- PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 8 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -56.2% |
| Current ratio | 1,903% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 5 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 2 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -431k | DKK 419k |
| Net profit | DKK -1.7m | DKK -14k |
| Equity | DKK -1.7m | DKK -24k |
| Total assets | DKK 3.0m | DKK 48k |
| Cash | DKK 2.3m | – |
| Short-term debt | DKK 160k | – |
| Avg. employees | 2 | – |
Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 179 | ||
| 1 Jan 2024 – 31 Dec 2024 | 177 | ||
| 1 Jan 2023 – 31 Dec 2023 | 144 | ||
| 1 Jan 2022 – 31 Dec 2022 | 150 | ||
| 1 Jan 2021 – 31 Dec 2021 | 94 | ||
| 1 Jan 2020 – 31 Dec 2020 | 103 | ||
| 1 Jan 2019 – 31 Dec 2019 | 128 | ||
| 13 Sep 2018 – 31 Dec 2018 | 123 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Aria Aminzadeh | Current | |
| CEO | Rene Jørgensen | ||
| CEO | Kasper Gubba Ørtenblad | ||
| Board | Per Bo Pedersen Fischer | Current | |
| Board | Rene Jørgensen | Current | |
| Board | Sten Verland | Current | |
| Board | Aria Aminzadeh | Current | |
| Board | Paul Jefferson Hargreaves | Current | |
| Owner (33%) | Aminzadeh Holding ApS | Current | |
| Owner (33%) | Dr RJ Holding ApS | Current | |
| Owner (0%) | Century House Holding ApS | Current | |
| Owner (100%) | Gubba Holding ApS | ||
| Owner (25%) | Gubba Holding ApS | ||
| Owner (33%) | Aminzadeh Holding ApS | ||
| Owner (33%) | Dr RJ Holding ApS | ||
| Owner (50%) | Aminzadeh Holding ApS | ||
| Owner (50%) | Dr RJ Holding ApS | ||
| Owner (50%) | Rene Jørgensen | ||
| Owner (33%) | Aria Aminzadeh | ||
| Owner (33%) | Rene Jørgensen | ||
| Owner (33%) | Aria Aminzadeh | ||
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | Current | |
| Auditor | Revisionshuset Tal & Tanker Statsautoriseret Revisionspartnerselskab | ||
| Auditor | JS Revision, Godkendt Revisionsaktieselskab | ||
| Auditor | Grant Thornton, Godkendt Revisionspartnerselskab | ||
| Founder | Gubba Holding ApS | Current |
The CEOs' other companies
Kasper Gubba Ørtenblad – 2 other companies
- KG Advisory ApS Active
- Roxiant ApS Opløst
Address history (3 moves)
| c/o René Jørgensen, Skjalm Hvides Gade 12, 3. th, 1728 København V | |
| c/o René Jørgensen, Egeskellet 6, 2000 Frederiksberg | |
| c/o SUND Hub, Nørre Allé 41, 2200 København N | |
| c/o CSE, Porcelænshaven 26, 2., 2000 Frederiksberg |
Former names
| Proxi Biotech ApS | – now |
| PrOxi Biotech ApS | – |
| PrOxi Biotech IVS | – |
Other companies at the same address
- Christen Christensen Holding IVS Bankrupt
- Dr RJ Holding ApS Active
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about Proxi Biotech ApS
Has Proxi Biotech ApS gone bankrupt?
No, Proxi Biotech ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Proxi Biotech ApS?
Our model estimates a bankruptcy risk of 1.0% over the next 12 months (low risk), which is 0.7 times the average for Danish companies.
Who is the CEO of Proxi Biotech ApS?
Aria Aminzadeh is the CEO of Proxi Biotech ApS.
Who is the auditor of Proxi Biotech ApS?
Proxi Biotech ApS most recently used PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB.
When was Proxi Biotech ApS founded?
Proxi Biotech ApS was founded on 13 September 2018.
What is the equity of Proxi Biotech ApS?
Equity was DKK -1.7m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.